Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Tempus AI — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Tempus AI trades at $66.53 (market cap $12.39B). The key difference: Tempus AI is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Tempus AI for 23 Days on average.
| KYMR | TEM | |
|---|---|---|
Market Cap | $8.87B | $12.39B |
Volume | 779,107 | 4,141,569 |
Sector | Health | Broad Market / Factor |
52-Week High | $127.31 | $92.45 |
52-Week Low | $55.80 | $41.55 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $8.26B | $13.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tempus AI (TEM) trades at $68.22, up 0.34% with a bullish technical signal despite negative profitability. The stock shows strong analyst support with 64% buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and ESMO conference presentations highlight ongoing innovation, while Q2 2026 earnings beat expectations with 22% revenue growth. Cash flow remains positive primarily from financing activities.
While TEM demonstrates strong revenue growth and product innovation, significant risks persist including negative net margins (-17.77%) and substantial insider selling. The stock's high P/B ratio of 27.84 suggests premium valuation despite unprofitability. Near-term catalysts include Q3 earnings and ESMO presentations, but investors should weigh growth potential against persistent losses and competitive pressures in AI healthcare.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
